20430-72-2

Basic information

• Product Name: 7-METHOXY-2-PHENYL-QUINOLIN-4-OL
• Synonyms: 4(1H)-quinolinone, 7-methoxy-2-phenyl-; 4-Quinolinol, 7-methoxy-2-phenyl-; 7-Methoxy-2-phenylquinolin-4(1H)-one; 7-Methoxy-2-phenylquinolin-4-ol
• CAS NO: 20430-72-2
• Molecular Formula: C₁₆H₁₃NO₂
• Molecular Weight: 251.28
• Mol File: 20430-72-2.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 430.7°C at 760 mmHg
• Flash Point: 214.3°C
• Appearance: /
• Density: 1.206g/cm³
• Vapor Pressure: 1.27E-07mmHg at 25°C
• Refractive Index: 1.614
• CAS DataBase Reference: 7-METHOXY-2-PHENYL-QUINOLIN-4-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 7-METHOXY-2-PHENYL-QUINOLIN-4-OL(20430-72-2)
• EPA Substance Registry System: 7-METHOXY-2-PHENYL-QUINOLIN-4-OL(20430-72-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41
• Safety Statements: 26-39
• WGK Germany: 3
• Hazardous Substances Data: 20430-72-2(Hazardous Substances Data)

Usage

General Description

7-METHOXY-2-PHENYL-QUINOLIN-4-OL, also known as canthin-6-one, is a chemical compound with potential pharmaceutical applications. It belongs to the class of quinoline alkaloids and is known for its anti-inflammatory, antitumor, and neuroprotective properties. It has been studied for its potential use in the treatment of various diseases, including cancer and Alzheimer's. 7-METHOXY-2-PHENYL-QUINOLIN-4-OL has exhibited promising results in laboratory experiments, showing potential as a therapeutic agent for a range of medical conditions. Its unique chemical structure and biological activities make it a subject of interest in the pharmaceutical and medical research fields.

InChI:InChI=1/C16H13NO2/c1-19-12-7-8-13-15(9-12)17-14(10-16(13)18)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)

Upstream product

• 873970-07-1 4-hydroxy-7-methoxy-2-phenyl-quinoline-3-carboxylic acid ethyl ester 
• 873383-40-5 4-hydroxy-7-methoxy-2-phenyl-quinoline-3-carboxylic acid 
• 1256842-40-6 ethyl 3-cyano-3-(3-methoxyphenylamino)-3-phenylpropanoate 
• 855239-80-4 N-(2-acetyl-5-methoxyphenyl)benzamide 
• 94-02-0 ethyl 3-oxo-3-phenylpropionate 
• 536-90-3 m-Anisidine 
• 57183-42-3 (E)-3-(3-Methoxy-phenylamino)-3-phenyl-acrylic acid ethyl ester 
• 98-88-4 benzoyl chloride 
• 445305-75-9 C₁₈H₁₉NO₃ 
• 101-84-8 diphenylether 
• 80819-63-2 N-(3-methoxy-phenyl)-benzimidoyl chloride 
• 5877-59-8 N-benzylidene-m-anisidine 
• 3446-58-0 3-oxo-3-phenylpropanamide 

Downstream Products

• 189816-05-5 4-chloro-7-methoxy-2-phenylquinoline 
• 483-51-2 7-methoxy-1-methyl-2-phenyl-1H-quinolin-4-one 
• 30034-40-3 7-hydroxy-2-phenylquinolin-4(1H)-one 
• 87741-95-5 7-hydroxy-2-phenylquinoline 
• 21255-17-4 7-methoxy-2-phenylquinoline 
• 1108657-02-8 C₂₈H₃₃N₃O₅ 
• 1108657-20-0 C₃₆H₄₁N₃O₅ 
• 1108657-00-6 C₃₅H₃₉N₃O₅ 
• 918650-48-3 phenylmethyl (2S)-2-amino-4-(7-methoxy-2-phenyl(4-quinolyloxy))butanoate hydrochloride 
• 1108657-27-7 C₃₇H₄₆N₄O₆ 
• 1108657-04-0 C₃₆H₄₄N₄O₆ 
• 1108657-23-3 C₂₉H₃₅N₃O₅ 
• 332181-53-0 (RS)-7-methoxy-4-oxiranylmethoxy-2-phenyl-quinoline 

Relevant articles and documents

Sulfone-Mediated SNAr Reaction as a Powerful Tool for the Synthesis of 4-Quinolinyl Ethers and More-Application to the Synthesis of HCV NS3/4a Protease Inhibitor BI 201420

An efficient general methodology for the synthesis of 4-quinolinyl ethers is demonstrated via a highly reactive SNAr reaction of 4-quinolinyl sulfones with a range of structurally diversified 1°, 2°, and 3° alcohols with a wide substrate scope and high yields. By adapting this methodology, a convergent synthesis of a complex target of HCV NS3/4a protease inhibitor BI 201420 was accomplished.

Microwave-assisted synthesis of polysubstituted 4-quinolones from deprotonated α-aminonitriles

The α-alkylation of deprotonated N-aryl-α-aminonitriles with α-bromoesters furnishes intermediates that can be cyclized to 4-quinolones upon microwave irradiation. Alternatively, base-induced dehydrocyanation of the alkylation products furnishes enaminoes

NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The embodiments provide compounds of the general Formulae I, II, III, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.